Alvotech ALVO 深 滬
等待開盤 08-10 09:30:00 美东时间
3.81
+0.010
+0.26%
華盛通- 最 高3.85
- 今 開3.83
- 成交量 34.20万股
- 最 低 3.735
- 昨 收 3.80
- 總市值 12.89亿
- 52周最高 9.25
- 市盈率 靜 39.77
- 換手率 0.10%
- 52周最低 2.94
- 委 比 -10.71%
- 總股本 3.38亿
- 歷史最高 18.00
- 量 比 0.37
- 振 幅 3.03%
- 歷史最低 2.94
- 每 手 1
- 風險率 1.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多SA Asks: What's the outlook for Big Pharma M&A?
Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY) was in merger talks with AstraZeneca (AZN), a development that was later denied by...
08-09 03:28
Alvotech shares are trading higher. The company announced the FDA has closed its inspection of its Reykjavik manufacturing facility, classifying the site as Voluntary Action Indicated.
Alvotech shares are trading higher. The company announced the FDA has closed its inspection of its Reykjavik manufacturing facility, classifying the site as Voluntary Action Indicated.
07-29 23:06
Alvotech announces successful closure of FDA inspection of manufacturing facility
Alvotech announced that the U.S. FDA has closed its inspection of the company's manufacturing facility in Reykjavik, Iceland, with the site classified as Voluntary Action Indicated (VAI). This reflects the company's efforts to strengthen its quality systems and manufacturing operations. Alvotech has recently resubmitted Biologics License Applications (BLAs) for two biosimilar candidates, AVT05 (biosimilar to Simponi®) and AVT06 (biosimilar to Eyl...
07-29 13:25
Transactions of Managers and Closely Associated Persons
Celtic Lux Holdings S.a. r.l. has filed two documents with the Luxembourg CSSF regarding transactions involving the pledging of 88,940,619 shares and 7,007,321 depository receipts in Alvotech by managers and closely associated persons. The transactions occurred on June 26, 2026.
07-03 20:01
Alvotech与GoldenTree Asset Management达成7500万美元额外定期贷款安排
生物科技公司奥维泰克获得由金树资产管理公司牵头提供的7500万美元额外定期贷款安排。 此前该公司已完成1.65亿美元股权融资，两轮融资合计为公司带来2.4亿美元...
07-01 16:09
Alvotech Strengthens Liquidity With $75M Term Loan, Building On Recent $165M Equity Raise For Total $240M In New Capital
— $75 million additional term loan facility maturing December 31, 2027, led by GoldenTree Asset Management — Follows recent $165m equity raise strengthening cash position — Including equity financing and undrawn loan facility, Alvotech has secured access to $240 million in new capital — Funds will s...
07-01 16:05
Alvotech further strengthens liquidity by securing term loan facility of $75 million
Alvotech has secured a $75 million additional term loan facility maturing in December 2027, led by GoldenTree Asset Management. This follows a recent $165 million equity raise, giving the company access to $240 million in new capital. The funds will support its R&D pipeline and global product launches. The financing reflects confidence in Alvotech's growth strategy and ability to expand patient access to affordable biosimilar medicines.
07-01 08:00
Transactions of Managers and Closely Associated Persons
Celtic Lux Holdings S.a. r.l. (formerly Alvogen Lux Holdings S.a. r.l.) has acquired 10,133,333 shares in Alvotech at USD 3.75 per share on June 16, 2026, as notified to the Luxembourg CSSF.
06-22 22:48
Teva submits NDA for ecopipam for pediatric Tourette's
Teva Pharmaceutical Industries (TEVA) has submitted an NDA to the US FDA seeking approval of ecopipam for pediatric Tourette syndrome. The application is supported by phase 3 data that found ecopipam ...
06-19 05:20
